Results 181 to 190 of about 1,583,699 (313)
CD226+CD8+ T cells express elevated levels of RUNX2, exhibit higher proliferation capacity, cytokines and cytolytic molecules expression, and migratory capacity. In contrast, CD226−CD8+ T cells display an exhausted phenotype associated with the increased expression of co‐inhibitory receptors and impaired effector functions.
Maryam Rezaeifar+4 more
wiley +1 more source
Opening Doors for Open Access [PDF]
openaire +2 more sources
Triacsin C inhibition of the acyl‐CoA synthetase long chain (ACSL) family decreases multiple myeloma cell survival, proliferation, mitochondrial respiration, and membrane potential. Made with Biorender.com. Multiple myeloma (MM) is an incurable cancer of plasma cells with a 5‐year survival rate of 59%.
Connor S. Murphy+12 more
wiley +1 more source
Does open-access mammography and ultrasound delay the diagnosis of breast cancer?
Abdulwahid M. Salih, W.M. Webb, T Bates
openalex +1 more source
Power flow tracing for transmission open access [PDF]
Wei Ping, Bin Yuan, Yixin Ni, F.F. Wu
openalex +1 more source
Transient receptor potential melastatin‐4 (TRPM4) is overexpressed in prostate cancer (PCa). Knockout of TRPM4 resulted in reduced PCa tumor spheroid size and decreased PCa tumor spheroid outgrowth. In addition, lack of TRPM4 increased cell death in PCa tumor spheroids.
Florian Bochen+6 more
wiley +1 more source
Pancreatic ductal adenocarcinoma (PDAC) is a disease with very poor prognosis due to therapeutic limitations. We investigated the antitumor effects of cystatin A (CSTA) in PDAC murine models. We are first to confirm that CSTA enhances T helper type 1‐mediated antitumor effects through promotion of dendritic cells and M1 macrophage activity. CSTA can be
Alessandro Nasti+8 more
wiley +1 more source
Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia+17 more
wiley +1 more source